首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

【24h】

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer

机译：TSR-011（ALK和TRK的有效抑制剂）在晚期实体瘤（包括耐克唑替尼的ALK阳性非小细胞肺癌）中的1 / 2a期研究（Pha）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Sachdev J.; Arkenau H. T.; Infante J. R.; Mita M. M.; Anthony S. P.; Natale R. B.; Ejadi S.; Wilcoxen K.; Kansra V.; Laken H.; Hughes L.; Martell R.; Weiss G. J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer [J] . Sachdev J., Arkenau H. T., Infante J. R., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：TSR-011（ALK和TRK的有效抑制剂）在晚期实体瘤（包括耐克唑替尼的ALK阳性非小细胞肺癌）中的1 / 2a期研究（Pha）
2. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study (vol 14, pg 1233, 2019) [J] . Camidge D. R., Dziadziuszko R., Peters S. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第11期

机译：更新了EML4-ALK融合变体对全球III期III阶段ALEX研究中未处理的ALK阳性晚期非小细胞肺癌效果的疗效和安全性数据及影响（Vol 14，PG 1233,2019）
3. MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX) [J] . Young Kim, Toyoaki Hida, Hiroshi Nokihara, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：AL27.03 alectinib（ALC）与屈曲非小细胞肺癌（ALK + NSCLC）中的冰水序（CRZ）：III期研究的主要结果（J-ALEX）
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Patient-reported outcomes in a phase II North American study of alectinib in patients with ALK-positive crizotinib-resistant non-small cell lung cancer [O] . Sai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, 2018

机译：北美alectinib在ALK阳性耐克唑替尼的非小细胞肺癌患者的II期北美研究中的患者报告结果
7. Phase I study of safety and pharmacokinetics for CT-707 in ALK-positive advanced non-small cell lung cancer [O] . Y-K Shi, X.Z. Hao, P. Xing, 2017

机译：I阶段研究CT-707在ALK阳性晚期非小细胞肺癌中的安全性和药代动力学研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号